Capital Signal: Brisbane Broncos are back

FY25 Guidance: EBITDA NZ$106-109M, NPAT NZ$14-16M
Previous Period: Not stated
Context: Economic challenges in NZ/Australia

Key Drivers: "Despite this decline, there are encouraging signs that the downward trend is beginning to level out. In the last three months, our overall daily sales activity has shown signs of stabilisation"

Standout Metric: Net debt reduced to NZ$232M from NZ$276M

FY26 Guidance: Revenue $80-90M, EBITDA $20-27M
Previous Period: FY25 Revenue $66.1M, EBITDA $16.1M
Growth: +$14M Revenue (+21%), +$11M EBITDA (+68%)

Key Drivers: "FY25 marked an excellent year for Chrysos. We achieved our original Revenue and EBITDA guidance and saw our EBITDA margin improve to 24% compared to 20% in FY24"

Standout Metric: 11 PhotonAssay units deployed in FY25, Master Services Agreement with Newmont

FY25 Result: $17.4M EBITDA
Previous Period: Up 14% vs prior year
Performance: New high-water marks across all operational metrics

Key Drivers: "By all measures, FY25 has been a solid year. Operationally, all key metrics have improved for LGI from biogas recovery, megawatt hours of electricity and generated ACCUs"

Standout Metric: 43% increase in electricity generating capacity, 12MW/24MWh battery project with NSW Government

FY25 Guidance: EBITDA $8.5-9.5M, NPAT $2.75-2.85M
Previous Period: Not provided
Outlook: Stronger second half performance

Key Drivers: "2HFY25 has been an improvement on 1HFY25 both in terms of revenue and profitability and we plan to build upon this foundation into FY26"

Standout Metric: Six-year $65M Collins Class submarine contract renewal

Half-Year Result: Net Profit $8.69M (achieved)
Previous Period: $6.30M in 2024
Growth: +$2.39M (+38%)

Key Drivers: Additional NRL home game, increased membership and corporate sales

Standout Metric: Received $1.75M for PNG NRL team partnership

Raise Type: Placement + SPP
Issue Price: $5.51 per share
Premium/Discount: No discount to last close

Use of Funds: Acquisition of M1 telecommunications business

Standout Metric: No discount placement (premium pricing at par)

Raise Type: Placement + SPP
Issue Price: $0.042 per share
Key Terms: Strategic investment with board representation

Use of Funds: General working capital for exploration projects

Standout Metric: Strategic investment included board representation (Amy Jiang appointed)

Raise Type: Placement
Issue Price: $0.045 per share
Key Terms: 99.6% shareholder approval for acquisition

Use of Funds: Acquisition of Learnt Global Group

Standout Metric: 99.6% shareholder approval for acquisition

Raise Type: SPP
Issue Price: $0.057 per share
Premium/Discount: 20% discount to market

Use of Funds: 6 MW CETO project at BiMEP (Spain), business development

Standout Metric: 20% discount to market price (5-day VWAP)

Raise Type: Entitlement Offer
Issue Price: $0.035 per share
Key Terms: 1-for-2 basis + free options

Use of Funds: Commercialization of EdenCrete® products and OptiBlend™ system

Standout Metric: Significant price surge (+31.43%) following announcement

Raise Type: Entitlement Offer
Issue Price: $0.001 per share
Premium/Discount: 50% discount to market

Use of Funds: Drilling of White Hills copper-gold project

Standout Metric: 50% discount to market price

Raise Type: SPP Extension
Details: Closing date extended to September 2, 2025
Purpose: Allow shareholders to review FY25 results

Key Context: Extension to align with FY25 annual results release

Standout Metric: Positive market reaction (+5.13%) to extension

Raise Type: Placement
Amount: ~$2.5M (first tranche)
Issue Price: $0.04 per share

Use of Funds: Clinical development of TRP-8803

Standout Metric: Strong positive price reaction (+4.76%) with high volume